Increased expression of proto-oncogene survivin predicts Joint destruction and persistent disease activity in early rheumatoid arthritis

Annals of Medicine

Volumn 42, Issue 1, 2010, Pages 45-54

  Svensson, Björn ^a   Hafström, Ingiäld ^b   Forslind, Kristina ^a,c   Albertsson, Kristina ^b   Tarkowski, Andrej ^d   Bokarewa, Maria ^d  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c HELSINGBORG HOSPITAL   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Oncogenes; Prognosis; Remission; Rheumatoid arthritis; Survivin

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; SURVIVIN;

ADULT; ARTICLE; BONE DESTRUCTION; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTO ONCOGENE; RHEUMATOID ARTHRITIS; X RAY;

ADULT; AGED; ANTIBODIES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; METHOTREXATE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; PEPTIDES, CYCLIC; PROSPECTIVE STUDIES; RHEUMATOID FACTOR; SULFASALAZINE; TREATMENT OUTCOME;

EID: 75149157986     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890903376280     Document Type: Article

References (27)

1. Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis: Work disability: a prospective 18 year study of 823 patients. J Rheumatol. 1998;25:2108-2117
2. Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum. 2000;29:305-320
3. Harrison BJ, Symmons DP, Brennan P, Barrett EM, Silman AJ. Natural remission in infl ammatory polyarthritis: issues of defi ni-tion and prediction. Br J Rheumatol. 1996;35:1096-1100
4. van Aken J, van Dongen H, le Cessie S, Allaart CF, Breedveld FC, Huizinga T W. Comparison of long term outcome of patients with rheumatoid arthritis presenting with undif-ferentiated arthritis or with rheumatoid arthritis: an observational cohort study. Ann Rheum Dis. 2006;65:20-25
5. Gorman JD, Lum RF, Chen JJ, Suarez-Almazor ME, Thomson G, Criswell LA. Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3,240 rheumatoid arthritis patients. Arthritis Rheum. 2004;50:400-412
6. Forslind K, Ahlmén M, Eberhardt K, Hafström I, Svensson B. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis. 2004;63:1090-1095
7. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, et al. Anti-citrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting fi ve year radiographic damage. Ann Rheum Dis. 2003;62:120-126
8. Bukhari M, Thomson W, Naseem H, Bunn D, Silman A, Symmons D, et al. The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in infl ammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Rheum. 2007;56:2929-2935
9. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146:797-808.
10. Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM. Survivin: A promising tumor biomarker. Cancer Lett. 2007;249:49-60.
11. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46-54.
12. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfi lled promises and open questions. Carcino-genesis. 2007;28:1133-1139
13. Firestein GS, Echeverri F, Yeo M, Zvaifl er NJ, Green DR. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci USA. 1997;94:10895-10900
14. Pap T, Franz JK, Hummel KM, Jeisy E, Gay R, Gay S. Activation of synovial fi broblasts in rheumatoid arthritis: lack of expression of the tumour suppressor PTEN at sites of invasive growth and destruction. Arthritis Res. 2000;2:59-64.
15. Pap T, Nawrath M, Heinrich J, Bosse M, Baier A, Hummel KM, et al. Cooperation of Ras-and c-Myc-dependent pathways in regulating the growth and invasiveness of synovial fi bro blasts in rheumatoid arthritis. Arthritis Rheum. 2004;50:2794-2802
16. Hashiramoto A, Sano H, Maekawa T, Kawahito Y, Kimura S, Kusaka Y, et al. C-myc antisense oligodeoxynucleotides can induce apoptosis and down-regulate Fas expression in rheumatoid synoviocytes. Arthritis Rheum. 1999;42:954-962
17. Bokarewa M, Lindblad S, Bokarew D, Tarkowski A. Balance between survivin, a key member of the apoptosis inhibitor family, and its specifi c antibodies determines ero-sivity in rheumatoid arthritis. Arthritis Res Ther. 2005;7: R349-58.
18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classifi cation of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324
19. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modifi ed disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38:44-8.
20. Prevoo MLL, van Gestel AM, vańt Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol. 1996;35:1101-1105
21. Mäkinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis. 2005;64:1410-1413
22. Ekdahl C, Eberhardt K, Andersson SI, Svensson B. Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol. 1988;17:263-271
23. van der Heijde DM, van Leeuwen MA, van Riel PL, Koster AM, van 't Hof MA, van Rijswijk MH, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum. 1992;35:26-34.
24. Gossec L, Dougados M, Goupille P, Cantagrel A, Sibilia J, Meyer O, et al. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis. 2004;63:675-680
25. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis. 2004;63:1085-1089
26. Baran M, Möllers LN, Andersson S, Jonsson IM, Ekwall AK, Bjersing J, et al. Survivin is an essential mediator of arthritis interacting with urokinase signalling. J Cell Mol Med. 2009 Feb 27 (Epub ahead of print).
27. Mera S, Magnusson M, Tarkowski A, Bokarewa M. Extracellular survivin up-regulates adhesion molecules on the surface of leukocytes changing their reactivity pattern. J Leukoc Biol. 2008;83:149-155